Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Calcium, Magnesium, Potassium, And Sodium Oxybates · Xywav, JZP258

Small molecule · Agonist of GABA B receptor (GABBR1) · developed by Jazz

Approved FDA, Jul 2020
JAZZ Developer
2 Registered trials

What is Calcium, Magnesium, Potassium, And Sodium Oxybates?

Xywav is a mixture of calcium, magnesium, potassium, and sodium oxybates (gamma-hydroxybutyrate). It is a CNS depressant hypothesized to work through GABA B receptor actions at noradrenergic, dopaminergic, and thalamocortical neurons.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Xywav, JZP258
Drug type
Small molecule
Targets
GABA B receptor (GABBR1)
Mechanism
Agonist of GABA B receptor (GABBR1)
Pathways
noradrenergic neuron signaling, dopaminergic neuron signaling, thalamocortical signaling
Therapy area
Neurology
Developer
Jazz (JAZZ)
FDA status
Approved as Xywav (July 21, 2020), NDA212690 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 1, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05875974 Phase 4 Idiopathic Hypersomnia Completed JAZZ
NCT07625280 Phase 3 Narcolepsy Recruiting JAZZ

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Idiopathic HypersomniaNarcolepsy

More from Jazz

Asparaginase Erwinia chrysanthemi FDA approved Daunorubicin And Cytarabine Liposome FDA approved Defibrotide FDA approved Lurbinectedin FDA approved Zanidatamab FDA approved CBD-OS Phase 3 Flezurafenib Phase 1 JZP269 Phase 1 JZP926 Phase 2/3 Nabiximols Phase 2 ONC206 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the JAZZ page.

Follow JAZZ, the company behind Calcium, Magnesium, Potassium, And Sodium Oxybates

See JAZZ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

JAZZ catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.